Study endpoints and assessments
ADVERSE EVENTS
The primary safety endpoints were the incidence and frequency of adverse events (AEs) and serious adverse events (SAEs), including injection site reactions, and these were summarized descriptively by treatment group and cohort. Further primary endpoints were PK parameters including, but not limited to, area under the plasma‐concentration time curve (AUC), maximum plasma concentration (Secondary endpoints were the maximal decrease from baseline (the last assessment prior to the first study dose) in free soluble IL‐33 (sIL‐33); a maximal increase from baseline in total sIL‐33 levels in serum summarized by cohort (and injection site for cohorts 1 and 2); and the incidence and prevalence of anti‐GSK3772847 antibodies and plasma 4β‐hydroxycholesterol/cholesterol (4βOHC/C) ratio (pre‐treatment and following dosing of GSK3772847), summarized by cohort (and injection site for cohorts 1 and 2) over time.Other endpoints included 12‐lead ECGs, clinical laboratory safety tests, vital signs, blood eosinophil levels, free and total sIL‐33 levels in serum, and GSK3772847 levels in the serum, summarized by cohort (and injection site for cohorts 1 and 2) over time. All endpoints were summarized descriptively.